Chiesi Group, an Italy-based biopharmaceutical leader with nearly 90 years of history, is recognized for its focus on innovation and sustainability. The company posted revenues exceeding €3 billion ($3.24 billion) in 2023, marking a 10 percent increase from the previous year, and maintaining a strong earnings performance with a nearly 30 percent EBITA margin for the fourth consecutive year.

Innovation and Research at the Heart of Chiesi’s Strategy

Chiesi’s commitment to innovation is evident in its significant research and development investments, which accounted for 23.8 percent of its 2023 sales revenue. The company is a leader in pharmaceutical patents, holding over 6,200 globally. A major milestone in 2023 was the opening of its Biotech Center of Excellence in Parma, Italy. With a €400 million investment, the facility focuses on developing monoclonal antibodies, enzymes, and proteins. By integrating research and industrial production, Chiesi aims to accelerate the delivery of treatments in respiratory health, specialty care, and rare diseases.

Giuseppe Accogli, CEO of Chiesi Group, commented, “The Biotech Center of Excellence represents a leap forward in our mission to drive innovation, expand production capabilities, and foster partnerships.”

Strengthening Global Partnerships: Focus on China

Chiesi’s global strategy also includes strengthening collaborations with international markets. The Chiesi China Marco Polo Project, launched in October 2022, exemplifies the synergy between Italian innovation and China’s healthcare needs. This initiative accelerates the introduction of innovative treatments while fostering cultural and scientific exchanges between Italy, China, and Europe.

Chiesi’s presence in China was bolstered in 2023 with the launch of its triple-combination inhaler for chronic obstructive pulmonary disease (COPD), included in China’s National Reimbursement Drug List, making it more accessible to patients. The company has also provided solutions for premature infant care, further contributing to China’s healthcare advancements.

Accogli emphasized, “The Marco Polo Project underscores our commitment to creating shared value, linking Italy’s medical heritage with China’s evolving healthcare system.”

Leading Italy’s Sustainability Efforts

As one of the first pharmaceutical companies to achieve B Corp certification in 2019, Chiesi has been at the forefront of sustainability within the industry. The company’s environmental, social, and governance (ESG) strategy for 2023-2028 outlines a commitment to achieving net-zero emissions by 2035. A key part of this strategy is the development of a new generation of pressurized metered-dose inhalers with a 90 percent lower carbon footprint than traditional models, backed by an investment of over €350 million.

Chiesi also supports global environmental initiatives, including reforestation and ecosystem restoration projects along historical trade routes like the Silk Road. The company’s efforts in Gansu province, China, where it is involved in combating desertification, demonstrate Italy’s commitment to environmental stewardship on a global scale.

Expanding Partnerships in Healthcare

Chiesi has continued to grow its global network of partnerships to drive medical innovation. In November 2023, it entered a licensing agreement with Chengdu-based Haisco Pharmaceutical Group to co-develop and commercialize respiratory treatments, marking a significant step in its global collaboration strategy. Additionally, Chiesi’s collaboration with Oak Hill Bio aims to address complications in extremely premature infants, reinforcing its commitment to supporting vulnerable populations.

The company also expanded its rare disease portfolio, with the U.S. FDA approval in December 2023 of its topical gel for epidermolysis bullosa. This approval, following earlier approvals in Europe and the U.K., solidifies Chiesi’s role in tackling complex medical challenges worldwide.

Promoting Cultural Diplomacy and Global Cooperation

Chiesi’s initiatives extend beyond healthcare, with a strong focus on cultural preservation and diplomacy. In collaboration with China, the company has supported the protection of intangible cultural heritage, such as Shu Embroidery and Hani ethnic polyphonic folk songs. These efforts enhance cultural exchanges and strengthen the ties between Italy and China, promoting both cultural and economic cooperation.

Deng Haoqing, President of Chiesi China, noted, “Through our work in healthcare and cultural preservation, Chiesi is helping lay a strong foundation for continued economic collaboration between Italy and China.”